Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (NASDAQ: XENE) has announced equity inducement grants to four new non-officer employees, consisting of 78,600 share options and 1,800 performance share units (PSUs). The grants, effective May 2, 2025, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $38.28 per common share, vesting over four years with a 10-year term. The PSUs will vest based on achieving predefined milestone-based objectives over approximately three years.
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (NASDAQ: XENE) ha annunciato l'assegnazione di incentivi azionari a quattro nuovi dipendenti non dirigenti, consistenti in 78.600 opzioni su azioni e 1.800 unità azionarie vincolate a risultati (PSU). Le assegnazioni, con efficacia dal 2 maggio 2025, sono state approvate dal Comitato per la Retribuzione e sono conformi alla Regola 5635(c)(4) del Nasdaq. Le opzioni azionarie hanno un prezzo di esercizio di 38,28 $ per azione ordinaria, maturano in un periodo di quattro anni e hanno una durata di dieci anni. Le PSU matureranno al raggiungimento di obiettivi specifici basati su traguardi definiti nell'arco di circa tre anni.
Xenon Pharmaceuticals è un'azienda biofarmaceutica focalizzata sulle neuroscienze, che sviluppa prodotti per i canali ionici per il trattamento dell'epilessia e della depressione. Il loro prodotto principale, azetukalner, è un apritore del canale potassico Kv7 in fase avanzata di sviluppo clinico per diverse indicazioni.
Xenon Pharmaceuticals (NASDAQ: XENE) ha anunciado concesiones de incentivos de acciones a cuatro nuevos empleados que no son oficiales, consistentes en 78.600 opciones sobre acciones y 1.800 unidades de acciones basadas en desempeño (PSUs). Las concesiones, vigentes a partir del 2 de mayo de 2025, fueron aprobadas por el Comité de Compensación y cumplen con la Regla 5635(c)(4) del Nasdaq. Las opciones sobre acciones tienen un precio de ejercicio de 38,28 $ por acción común, se consolidan en cuatro años y tienen un plazo de diez años. Las PSUs se consolidarán en función del logro de objetivos predefinidos basados en hitos durante aproximadamente tres años.
Xenon Pharmaceuticals es una empresa biofarmacéutica centrada en neurociencia que desarrolla productos para canales iónicos dirigidos a la epilepsia y la depresión. Su producto principal, azetukalner, es un activador del canal de potasio Kv7 en desarrollo clínico avanzado para múltiples indicaciones.
Xenon Pharmaceuticals (NASDAQ: XENE)는 비임원 신입 직원 4명에게 78,600주 주식매수선택권과 1,800주의 성과기반주식단위(PSU)를 부여한다고 발표했습니다. 이 부여는 2025년 5월 2일부로 효력이 발생하며, 보상위원회의 승인을 받았고 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 주식매수선택권의 행사가격은 보통주당 38.28달러이며, 4년간 권리확정(베스팅)되고 10년간 유효합니다. PSU는 약 3년간 미리 정해진 성과 목표 달성에 따라 권리확정됩니다.
Xenon Pharmaceuticals는 신경과학에 중점을 둔 바이오제약 회사로, 간질과 우울증 치료를 위한 이온 채널 제품을 개발하고 있습니다. 주력 제품인 아제투칼너는 다수 적응증을 대상으로 후기 임상 개발 중인 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (NASDAQ: XENE) a annoncé des attributions d'incitations en actions à quatre nouveaux employés non cadres, comprenant 78 600 options d'achat d'actions et 1 800 unités d'actions de performance (PSU). Ces attributions, effectives à partir du 2 mai 2025, ont été approuvées par le comité de rémunération et sont conformes à la règle 5635(c)(4) du Nasdaq. Les options d'achat d'actions ont un prix d'exercice de 38,28 $ par action ordinaire, acquièrent des droits sur quatre ans et ont une durée de dix ans. Les PSU seront acquises en fonction de l'atteinte d'objectifs prédéfinis basés sur des jalons sur environ trois ans.
Xenon Pharmaceuticals est une société biopharmaceutique axée sur les neurosciences, développant des produits ciblant les canaux ioniques pour l'épilepsie et la dépression. Leur produit phare, azetukalner, est un activateur du canal potassique Kv7 en phase avancée de développement clinique pour plusieurs indications.
Xenon Pharmaceuticals (NASDAQ: XENE) hat Aktienanreiz-Zuteilungen an vier neue nicht leitende Angestellte bekannt gegeben, bestehend aus 78.600 Aktienoptionen und 1.800 Performance-Aktieneinheiten (PSUs). Die Zuteilungen, wirksam ab dem 2. Mai 2025, wurden vom Vergütungsausschuss genehmigt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4). Die Aktienoptionen haben einen Ausübungspreis von 38,28 $ pro Stammaktie, vesten über vier Jahre und haben eine Laufzeit von zehn Jahren. Die PSUs werden basierend auf dem Erreichen vordefinierter Meilensteinziele über etwa drei Jahre vesten.
Xenon Pharmaceuticals ist ein biopharmazeutisches Unternehmen mit Fokus auf Neurowissenschaften, das Ionenkanal-Produkte für Epilepsie und Depression entwickelt. Ihr Hauptprodukt, Azetukalner, ist ein Kv7-Kaliumkanalöffner in der späten klinischen Entwicklungsphase für mehrere Indikationen.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units (“PSUs”). All of the foregoing share options and PSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of May 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
What type of equity grants did Xenon Pharmaceuticals (XENE) announce on May 2, 2025?
What is the exercise price for XENE's newly granted share options?
What is the vesting schedule for Xenon Pharmaceuticals' new share options?
What is Xenon Pharmaceuticals' (XENE) main product in development?
